Incyte Corporation
$ 100.46
-1.02%
04 Dec - close price
- Market Cap 19,926,755,000 USD
- Current Price $ 100.46
- High / Low $ 102.47 / 99.69
- Stock P/E 17.17
- Book Value 23.71
- EPS 5.91
- Next Earning Report 2026-02-18
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA 0.14 %
- ROE 0.30 %
- 52 Week High 109.28
- 52 Week Low 53.56
About
Incyte Corporation (INCY), headquartered in Wilmington, Delaware, is a prominent biopharmaceutical company dedicated to developing innovative therapies for oncology and other serious medical conditions. Since its inception in 1991, Incyte has achieved significant commercial success with its leading product, Jakafi, which treats myelofibrosis and polycythemia vera, while also advancing a robust pipeline of drug candidates targeting various malignancies. The company's commitment to precision medicine, coupled with strategic collaborations, positions it at the forefront of addressing critical unmet medical needs in the healthcare sector. Through its emphasis on scientific innovation and improved patient outcomes, Incyte is poised to maintain its influential role in the biopharmaceutical landscape.
Analyst Target Price
$95.57
Quarterly Earnings
| Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2025-10-28 | 2025-07-29 | 2025-04-29 | 2025-02-10 | 2024-10-29 | 2024-07-30 | 2024-04-30 | 2024-02-13 | 2023-10-31 | 2023-08-01 | 2023-05-02 | 2023-02-07 |
| Reported EPS | 2.26 | 1.57 | 0.8 | 1.43 | 0.54 | -1.82 | 0.64 | 1.06 | 1.1 | 0.99 | 0.37 | 0.62 |
| Estimated EPS | 1.64 | 1.47 | 0.76 | 1.55 | 0.79 | -1.55 | 0.84 | 1.16 | 1.02 | 0.83 | 0.76 | 0.58 |
| Surprise | 0.62 | 0.1 | 0.04 | -0.12 | -0.25 | -0.27 | -0.2 | -0.1 | 0.08 | 0.16 | -0.39 | 0.04 |
| Surprise Percentage | 37.8049% | 6.8027% | 5.2632% | -7.7419% | -31.6456% | -17.4194% | -23.8095% | -8.6207% | 7.8431% | 19.2771% | -51.3158% | 6.8966% |
Next Quarterly Earnings
| Dec 2025 | |
|---|---|
| Reported Date | 2026-02-18 |
| Fiscal Date Ending | 2025-12-31 |
| Estimated EPS | 1.92 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: INCY
2025-12-04 22:35:51
Incyte (NASDAQ:INCY) EVP Steven Stein sold 20,105 shares of the company's stock for over $2 million, representing a 24.15% reduction in his holdings. This sale occurred just after Incyte reported strong Q3 earnings, beating analyst expectations with $2.26 EPS and $1.37 billion in revenue. Analyst sentiment for Incyte is currently mixed, with a "Hold" consensus rating and a target price of $93.85.
2025-12-04 22:35:51
Incyte (NASDAQ:INCY) EVP Steven Stein sold 2,559 shares of the company's stock on December 1st at an average price of $102.96, totaling $263,474.64. This transaction reduced his stake by 2.49% to 100,327 shares. The biopharmaceutical company recently exceeded Q3 earnings and revenue estimates, and analysts currently hold a consensus "Hold" rating with a target price of $93.85.
2025-12-04 10:16:41
Incyte Corporation announced equity inducement awards to Richard Hoffman, their new Executive Vice President and General Counsel, under Nasdaq Listing Rule 5635(c)(4). These awards, effective December 1, 2025, include stock options, restricted stock units, and performance shares, designed to incentivize his employment. The grants are part of the Company’s 2024 Inducement Stock Incentive Plan.
2025-12-03 21:38:10
Michael James Morrissey, Vice President of Incyte Corp (INCY), filed a Form 4 on December 3, 2025, disclosing the surrender of 326 shares back to the company. The transaction, on December 1, 2025, was valued at $33,265, with shares priced at $102.04. This surrender was made to cover option exercise costs and/or resulting tax liability, leaving Morrissey with 85,838 direct holdings.
2025-12-03 21:30:00
Incyte Corporation announced equity inducement awards to Richard Hoffman, the Company’s new Executive Vice President and General Counsel, under Nasdaq Listing Rule 5635(c)(4). These awards, approved by the compensation committee, include stock options to purchase 43,301 shares, restricted stock units for 9,466 shares, and performance shares with a target of 23,665 shares. The grants, effective December 1, 2025, are an inducement for his employment, with vesting schedules tied to continued service and company performance.
2025-12-03 21:30:00
Incyte Corporation announced equity inducement awards granted to its new Executive Vice President and General Counsel, Richard Hoffman, under Nasdaq Listing Rule 5635(c)(4). These awards, approved by the compensation committee, include stock options, restricted stock units, and performance shares, all linked to his continued employment. The grants are intended to incentivize Mr. Hoffman's entry into employment with Incyte.
